Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,826,755,187 | $6,965,719,494 | $7,053,205,896 | $6,602,510,490 |
| - Cash | $681,486,000 | $350,008,000 | $385,113,000 | $494,126,000 |
| + Debt | $4,645,320,000 | $4,505,942,000 | $4,515,265,000 | $4,840,148,000 |
| Enterprise Value | $10,790,589,187 | $11,121,653,494 | $11,183,357,896 | $10,948,532,490 |
| Revenue | $1,112,796,000 | $1,106,685,000 | $1,053,400,000 | $1,144,124,000 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Gross Profit | $732,735,000 | $722,010,000 | $671,300,000 | $727,250,000 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| EBITDA | $316,467,000 | $439,424,000 | $181,269,000 | $193,007,000 |
| % Margin | 28.4% | 39.7% | 17.2% | 16.9% |
| Net Income | -$11,802,000 | $124,243,000 | -$103,200,000 | $23,789,000 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS Diluted | -3.74 | 39.12 | -32.62 | 7.51 |
| % Growth | -109.6% | 219.9% | -534.4% | – |
| Operating Cash Flow | $378,228,000 | $215,423,000 | $222,159,000 | $383,756,000 |
| Capital Expenditures | -$52,825,000 | -$75,068,000 | -$48,793,000 | -$45,088,000 |
| Free Cash Flow | $325,403,000 | $140,355,000 | $173,366,000 | $338,668,000 |